The RNAi treatment developer is clawing its way back after a rough start to 2020.
News & Analysis: Arrowhead Pharmaceuticals
Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
A leading company in the field of gene silencing is on track to develop several breakthrough therapies.
ARWR earnings call for the period ending March 31, 2020.
The collaboration between a pharmaceutical giant and a mid-cap biotech company may have accomplished the impossible.
After a stellar 2019, the biotech stock has lost 47% so far in 2020.
Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.
The clinical-stage biotech posted a revenue decline and a widening net loss in Q1. But no one cared.
ARWR earnings call for the period ending December 31, 2019.